Plain-English translation of NCT06624839 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing Gardasil Nine-valent HPV vaccine to see how well it works in people born male, particularly those living with HIV and those with a history of hormone therapy. The study measures whether the vaccine triggers a strong immune response in these groups by collecting blood samples and anal swabs before and after a three-dose vaccination series.
People living with HIV and those who have taken hormone therapy may not respond as well to vaccines as others do. This study wants to understand whether this medication works effectively in these populations and to help prevent HPV-related cancers in groups at higher risk.
You likely qualify if…
You likely don't qualify if…
You would receive three vaccine doses over six months (at the start, two months in, and six months in). Before your first dose and one month after your last dose, you would provide blood samples and anal swabs so researchers can measure your immune response. If any precancerous changes are found during the study, you may be referred for additional clinical evaluation and biopsies as part of your care.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States